The European Commission approved Moderna’s mCOMBRIAX on 21 April 2026 — the world’s first single-dose mRNA vaccine against both COVID-19 and influenza. Meanwhile, the US FDA refused to even review the standalone flu component it’s built on. Here’s the full story.